Table 2.
Lesion | Target (volume in ) |
|
|
|
|
HI (3D / 4D) | () | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
A | GTV (22.7) | 45.3 / 44.9 | 79.5 / 78.5 | 46.8 / 46.7 | 43.1 / 42.7 | 1.08 / 1.09 | 99.1 | ||||
ITV (31.1) | 45.1 / 44.7 | 79.0 / 78.0 | 46.7 / 46.7 | 42.6 / 38.9 | 1.10 / 1.20 | 91.7 | |||||
PTV (66.4) | 44.0 / 43.4 | 76.3 / 74.8 | 46.7 / 46.7 | 36.8 / 30.9 | 1.27 / 1.51 | 84.1 | |||||
B | GTV (12.4) | 42.7 / 40.4 | 73.1 / 67.6 | 43.4 / 43.2 | 41.1 / 39.8 | 1.06 / 1.08 | 98.2 | ||||
ITV (17.9) | 42.1 / 39.0 | 71.6 / 64.4 | 43.3 / 43.2 | 36.9 / 33.8 | 1.17 / 1.28 | 91.4 | |||||
PTV (39.3) | 41.1 / 37.8 | 69.2 / 61.7 | 43.3 / 43.2 | 31.7 / 26.4 | 1.37 / 1.64 | 83.5 | |||||
C | GTV (54.5) | 48.2 / 47.8 | 86.9 / 85.9 | 50.2 / 49.8 | 46.1 / 45.6 | 1.08 / 1.09 | 99.7 | ||||
ITV (87.0) | 48.0 / 47.4 | 86.4 / 84.8 | 50.2 / 49.8 | 44.7 / 44.1 | 1.12 / 1.13 | 99.1 | |||||
PTV (168.7) | 47.4 / 46.3 | 84.8 / 82.0 | 50.1 / 49.8 | 42.8 / 36.6 | 1.17 / 1.36 | 86.0 | |||||
D | GTV (6.68) | 55.3 / 55.0 | 116.5 / 115.5 | 55.8 / 55.6 | 54.3 / 53.9 | 1.02 / 1.03 | 99.6 | ||||
ITV (21.28) | 54.8 / 54.4 | 114.9 / 113.6 | 55.7 / 55.5 | 53.0 / 52.2 | 1.05 / 1.06 | 98.8 | |||||
PTV (71.36) | 52.7 / 50.7 | 108.2 / 102.1 | 55.6 / 55.4 | 46.3 / 35.3 | 1.20 / 1.57 | 76.5 | |||||
E | GTV (86.16) | 46.2 / 45.0 | 81.8 / 78.8 | 46.7 / 45.9 | 43.8 / 41.9 | 1.07 / 1.08 | 99.1 | ||||
ITV (100.5) | 46.0 / 44.8 | 81.3 / 78.3 | 46.6 / 45.8 | 43.2 / 41.2 | 1.08 / 1.11 | 97.0 | |||||
PTV (187.24) | 44.3 / 42.4 | 77.0 / 72.4 | 46.3 / 45.4 | 38.2 / 31.0 | 1.21 / 1.46 | 82.8 |
3D = three‐dimensional dose calculation; 4D = four‐dimensional dose calculation; ; ; ; ; HI = homogeneity index (the ratio of to ); = the percentage ratio of HI for 3D to 4D (). All doses in Gy.